Details for Patent: 9,700,530

Which drugs does patent 9,700,530 protect, and when does it expire?

Patent 9,700,530 protects KAPSPARGO SPRINKLE and is included in one NDA.

This patent has eight patent family members in seven countries.

Summary for Patent: 9,700,530

Title:	Capsule dosage form of metoprolol succinate
Abstract:	This disclosure provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units, wherein said capsule dosage form is bioequivalent to the marketed Toprol-XL® tablet. The extended-release capsule dosage form comprising coated discrete units can be sprinkled onto food to ease administration to patients who have difficulty swallowing tablets or capsules.
Inventor(s):	Sandeep Kumar VATS, Balaram MONDAL, Kalaiselvan Ramaraju, Romi Barat Singh
Assignee:	Sun Pharmaceutical Industries Ltd
Application Number:	US15/337,611
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form;

US Patent 9,700,530: Scope, Claim Construction, Expiration Risk, and Metoprolol Succinate Patent Landscape

US Patent 9,700,530 protects a metoprolol succinate extended-release capsule built around small, coated discrete units, such as pellets, granules, minitablets, or beads. Its principal commercial distinction is administration flexibility: the units must remain chemically stable and physically deliverable after dispersion in water, passage through a feeding tube, or sprinkling onto soft food.

The patent is narrower than a general metoprolol extended-release patent. A potentially infringing product must satisfy the capsule, coated-unit, particle-size, release, impurity, food-sprinkle, or feeding-tube limitations applicable to the asserted claim. The most commercially important claims are independent claims 1, 4, 10, and 11. Claims 2, 3, and 5-9 and 12-14 add narrower technical limitations.

What does US Patent 9,700,530 protect?

The patent protects an extended-release capsule dosage form of metoprolol succinate containing coated discrete units with controlled particle size and administration performance.

Core protected elements

Technical element	Claims affected	Practical significance
Metoprolol succinate	1, 4, 10, 11	Limits the patent to the succinate salt
Extended-release capsule	1, 4, 10, 11	Excludes ordinary immediate-release capsules and most tablets
Coated discrete units	1, 4, 10, 11	Requires multiparticulate dosage architecture
d90 of about 0.2-1.5 mm	1, 10, 11	Establishes a particle-size range
d90 of about 0.2-1.2 mm	2, 4	Narrower size limitation
Feeding-tube flowability	1	Requires functional performance after aqueous dispersion
At least 85% recovery through a feeding tube	4	Express quantitative delivery requirement
Related substances not above 0.50%	1, 10	Chemical stability limitation
Particle-size change of no more than 30%	3	Controls swelling, erosion, agglomeration, or disintegration
Soft-food sprinkle stability	10, 11	Protects administration with foods at different pH levels
Pellets, granules, minitablets, or beads	5, 12	Defines examples of the discrete units
Lubrication before capsule filling	6, 7, 13	Narrows manufacturing and handling configuration
NG, G, or J tube administration	8, 14	Targets enteral administration
Latex-free syringe dispersion	9	Adds a specific administration system

The patent does not broadly cover metoprolol succinate as an active ingredient, metoprolol extended release generally, or every multiparticulate metoprolol product. It targets a formulation that combines extended release with sprinkle and enteral-tube administration.

How should the independent claims be interpreted?

Claims 1, 4, 10, and 11 establish four overlapping but distinct infringement theories.

Claim 1: chemical stability and feeding-tube usability

Claim 1 requires:

1. An extended-release capsule dosage form;
2. Metoprolol succinate;
3. Coated discrete units;
4. A d90 between approximately 0.2 mm and 1.5 mm;
5. Dispersion in aqueous media for at least 10 minutes;
6. Desired flowability through a feeding tube; and
7. Related substances no higher than 0.50% by weight.

The claim combines structural and functional limitations. The particle-size range is structural. Flowability, dispersion behavior, and impurity content are performance limitations.

The phrase “desired flowability” is less precise than claim 4’s requirement of at least 85% recovery. In litigation, the patentee would likely rely on the specification, examples, test methods, feeding-tube dimensions, and product instructions to establish what constitutes acceptable flowability. The defendant would likely challenge the term if the patent does not provide an objective test or reproducible threshold.

Claim 4: quantitative feeding-tube recovery

Claim 4 is directed to coated units with a d90 between approximately 0.2 mm and 1.2 mm. After dispersion in aqueous media and delivery through a feeding tube of at least 10 French, at least 85% of metoprolol succinate must be recovered at the tube exit after at least 10 minutes.

This claim is more specific than claim 1 in two respects:

• The upper particle-size limit is 1.2 mm rather than 1.5 mm.
• It establishes an objective recovery threshold of 85%.

The “NLT 10 F” limitation means the claim covers tubes with a size of not less than 10 French. A product tested only through larger tubes may still fall within the claim, provided the claimed recovery result is met. The claim is directed to product performance, not merely the instruction to use an enteral tube.

Claim 10: impurity control after sprinkling

Claim 10 covers coated units with a d90 between approximately 0.2 mm and 1.5 mm that, after being sprinkled on soft foods with different pH levels and exposed for at least 30 minutes, contain no more than 0.50% total metoprolol succinate related substances.

This claim is important because it addresses food compatibility rather than feeding-tube delivery. A competing product could avoid claim 10 only by failing at least one limitation, such as:

• Using a different particle-size distribution;
• Producing more than 0.50% related substances under the specified test;
• Not being a coated-unit extended-release capsule;
• Not maintaining the claimed condition after 30 minutes; or
• Using an administration method outside the claim.

Claim 11: dissolution-profile preservation

Claim 11 requires a similar dissolution profile before and after exposure to soft foods at different pH levels for at least 30 minutes.

“Similar” is a potentially contested term. Its meaning depends on the specification, dissolution method, acceptance criteria, and any statistical comparison described in the patent. A regulatory bioequivalence standard is not automatically the same as a patent-law “similar dissolution profile” standard.

This claim can reach products that maintain chemical assay and impurity limits but alter drug release after contact with food. It therefore targets a different failure mode from claim 10.

How do the dependent claims narrow the patent?

The dependent claims add product-form, manufacturing, and administration limitations.

Multiparticulate form

Claims 5 and 12 specify pellets, granules, minitablets, or beads. These limitations are commercially relevant because a generic developer could choose a different unit architecture, although it would still need to avoid the broader independent claim if the alternative falls within “coated discrete units.”

Lubrication

Claims 6, 7, and 13 require lubrication before capsule filling. Claim 7 lists:

• Colloidal silicon dioxide;
• Stearic acid;
• Magnesium stearate;
• Calcium stearate;
• Talc;
• Hydrogenated castor oil;
• Sucrose esters of fatty acids;
• Microcrystalline wax;
• Yellow beeswax;
• White beeswax; or
• Mixtures of those materials.

These claims create a narrower process-linked product limitation. They are unlikely to capture every product using a lubricant unless the lubricant and timing limitations are satisfied.

Enteral administration

Claims 8 and 14 cover NG, G, and J tubes. Claim 9 further requires dispersion in a latex-free syringe before delivery. The claims focus on administration through a tube, not only the capsule as sold.

What formulation characteristics are protected?

The patent’s formulation protection is concentrated in four technical variables.

Particle size

The d90 requirement is central. d90 means that 90% of the measured particle population is at or below the stated size, subject to the measurement basis used.

The claimed ranges are:

Claim	d90 range
1, 10, 11	About 0.2 mm to 1.5 mm
2, 4	About 0.2 mm to 1.2 mm

Particle-size evidence will depend on sampling, measurement technology, dry versus wet measurement, aggregation treatment, and whether the measurement is performed before or after aqueous exposure. A product may produce materially different d90 results under laser diffraction, sieve analysis, or image analysis.

Aqueous dispersion

The claims impose a minimum dispersion period of 10 minutes for feeding-tube claims. The dispersion medium, temperature, agitation, volume, and holding conditions may affect:

• Pellet swelling;
• Coating integrity;
• Agglomeration;
• Sedimentation;
• Syringe withdrawal;
• Tube obstruction; and
• Drug recovery.

These parameters are likely to be important in both infringement testing and invalidity analysis.

Soft-food exposure

Claims 10 and 11 require exposure to soft foods with different pH levels for at least 30 minutes. The food matrix can affect the coating, release rate, impurity profile, and recovery. The precise food types and pH values are therefore material to claim testing.

Related substances

Claims 1 and 10 impose a maximum of 0.50% by weight. The analytical method must define which degradation products or process impurities count as “related substances.” A competing product can present risk even if its dissolution profile is acceptable, because impurity content is an independent limitation.

What generic entry risks exist for metoprolol succinate capsules?

The principal generic entry risk is not conventional metoprolol ER tablets. It is a multiparticulate capsule designed for sprinkle and enteral-tube administration.

Lower-risk design-around paths

A developer could reduce literal infringement risk by pursuing one or more of the following approaches:

Design choice	Potential effect
Use a tablet rather than a capsule	Avoids the capsule limitation, subject to other patent rights
Use a different particle architecture	May avoid “coated discrete units”
Use a d90 outside the claimed range	Avoids a central structural limitation
Avoid sprinkle labeling	May reduce risk under claims 10 and 11
Use a different delivery system	May avoid dependent tube-administration claims
Use a formulation that fails the claimed performance threshold	May avoid literal infringement but create regulatory or commercial disadvantages
Use a different metoprolol salt	May avoid claims limited to metoprolol succinate

These options may create separate regulatory, bioequivalence, manufacturability, or product-liability problems. A design that intentionally fails feeding-tube performance would not be attractive for a product positioned as an administration alternative.

What is the FDA and Orange Book relevance?

The commercial product most closely associated with this patent is Kapspargo Sprinkle, an extended-release metoprolol succinate capsule approved for oral use by swallowing, sprinkling on soft food, and, according to labeling, administration through certain feeding tubes. The FDA-approved labeling is the controlling regulatory source for approved dosage form, administration instructions, and product characteristics (U.S. Food and Drug Administration [FDA], n.d.-a).

The Orange Book determines whether a patent is listed against an approved drug product and whether an ANDA applicant must address it through certification. Patent listing, expiration, use codes, and exclusivity should be checked against the current FDA Orange Book entry rather than inferred from the patent claims alone (FDA, n.d.-b).

Paragraph IV implications

An ANDA applicant seeking approval before the relevant listed patent expiration could file:

• Paragraph I certification if no patent information is listed;
• Paragraph II certification if the listed patent has expired;
• Paragraph III certification accepting delayed approval until patent expiration; or
• Paragraph IV certification alleging that the patent is invalid, unenforceable, or not infringed.

A Paragraph IV notice can trigger patent litigation under the Hatch-Waxman Act. The statutory litigation framework includes a 45-day period for the patent owner or NDA holder to sue and a potential 30-month stay of approval, subject to statutory exceptions and court rulings (21 U.S.C. § 355(j)(2)(A)(vii), (j)(5)(B)(iii)).

The claim language creates several likely Paragraph IV positions:

1. The accused product does not contain coated discrete units.
2. Its d90 is outside the claimed range.
3. It does not meet the 85% feeding-tube recovery threshold.
4. It exceeds or does not meet the specified test conditions.
5. Its dissolution profile is not “similar” under the claim.
6. The claim is indefinite because terms such as “desired flowability” or “similar” lack objective boundaries.
7. The claims lack written description or enablement across the full particle-size and administration ranges.

When does US Patent 9,700,530 lose exclusivity?

The patent issued on July 11, 2017. Its expiration date cannot be reliably calculated from the claims or grant date alone because the statutory term depends on the relevant nonprovisional filing date, priority chain, patent-term adjustment, terminal disclaimers, and any patent-term extension.

The practical exclusivity timeline is therefore:

Event	Date or status
Patent grant	July 11, 2017
Statutory patent term	Generally 20 years from the relevant nonprovisional filing date
Patent-term adjustment	Must be confirmed from the USPTO patent record
Patent-term extension	Must be confirmed from FDA and USPTO records
Orange Book expiry	Must be confirmed from the current Orange Book listing
Earliest ANDA approval	Depends on certifications, litigation, exclusivity, and any settlement

The patent grant date is not the expiration date. Commercial diligence should use the USPTO Patent Center record and the current Orange Book entry.

How strong is the patent estate?

US 9,700,530 appears technically focused rather than broad. Its strength comes from the combination of multiple product-performance requirements:

• Controlled d90 particle size;
• Coated multiparticulates;
• Chemical stability after food or water exposure;
• Feeding-tube recovery;
• Preservation of dissolution after soft-food contact.

Those combinations may make a simple copy difficult. A competitor can, however, attack individual limitations through formulation testing and claim construction.

Strengths

• Claims target commercially meaningful administration features.
• Claim 4 includes an objective 85% recovery threshold.
• Claims cover both sprinkle and feeding-tube use.
• The formulation architecture may be difficult to replicate without similar testing results.
• The patent can create regulatory friction even if a competitor develops a nonidentical product.

Vulnerabilities

• “Desired flowability” may lack a clear objective boundary.
• “Similar” dissolution profiles may require specification-based construction.
• d90 results can vary with test methodology.
• The claims depend heavily on test conditions that may not be fully specified in the claim language.
• A tablet, noncapsule, nonmultiparticulate, or differently engineered product may avoid the claims.
• The patent does not cover all metoprolol succinate extended-release dosage forms.

What patent litigation and licensing issues affect the product?

The patent claims themselves contain no licensing terms, settlement provisions, or litigation history. Those matters are found in court dockets, FDA patent listings, assignment records, and commercial agreements rather than in the claim set.

For diligence, the relevant records are:

Issue	Primary source
Current patent owner and assignments	USPTO Patent Center and assignment database
Orange Book listing	FDA Approved Drug Products with Therapeutic Equivalence Evaluations
Patent litigation	PACER, district court dockets, and Federal Circuit opinions
ANDA status	FDA regulatory records and court filings
License or settlement	SEC filings, court-approved settlement documents, and transaction disclosures
Patent-term adjustment	USPTO patent record
Patent-term extension	FDA and USPTO records

No license should be assumed merely because a company markets the product or manufactures it under contract. Ownership, exclusive licensing, and manufacturing rights are separate legal positions.

How does US 9,700,530 compare with competing metoprolol products?

Product type	Administration	Multiparticulate capsule	Sprinkle/tube positioning	Relevance to US 9,700,530
Kapspargo Sprinkle	Capsule, soft food, feeding tube	Yes	Yes	Direct commercial relevance
Toprol-XL	Extended-release tablet	No	Generally not the same architecture	Limited direct overlap
Generic metoprolol ER tablets	Tablet	No	Usually not equivalent to sprinkle capsule use	Usually outside the principal claim structure
Conventional metoprolol capsules	Capsule	Product-specific	Product-specific	Requires element-by-element analysis
Alternative multiparticulate capsules	Capsule	Possibly	Depends on labeling and performance	Highest potential risk

The patent’s competitive value lies in administration flexibility, not merely once-daily metoprolol exposure.

What manufacturing and IP barriers exist?

The main manufacturing barriers are coating uniformity, particle-size control, low agglomeration, reproducible tube recovery, and maintenance of extended release after exposure to acidic or neutral soft foods.

A generic developer would likely need to control:

1. Core-unit production;
2. Drug-layer uniformity;
3. Extended-release coating thickness;
4. Final d90 distribution;
5. Lubricant blending;
6. Capsule fill-weight variation;
7. Aqueous dispersion behavior;
8. Feeding-tube recovery;
9. Food-contact dissolution; and
10. Related-substance formation.

These are both CMC requirements and potential infringement variables. A product may be bioequivalent yet fail to match the claimed sprinkle or tube-performance characteristics. Conversely, a product may satisfy the patent’s functional limitations while avoiding infringement only through a structural difference.

Key Takeaways

• US 9,700,530 is a focused formulation patent for metoprolol succinate extended-release capsules containing coated multiparticulates.
• The principal protected ranges are d90 values of approximately 0.2-1.5 mm and, in narrower claims, 0.2-1.2 mm.
• Claims 1 and 4 focus on aqueous dispersion and feeding-tube delivery.
• Claims 10 and 11 focus on soft-food sprinkling, impurity control, and preservation of dissolution.
• The patent does not broadly cover all metoprolol succinate extended-release products.
• The most important invalidity and noninfringement issues are particle-size measurement, objective meaning of “desired flowability,” interpretation of “similar” dissolution, and testing conditions.
• Generic risk is highest for a Kapspargo-like capsule with pellets or beads, sprinkle labeling, and enteral-tube administration.
• The exact patent expiration date requires confirmation from the USPTO patent-term record and the current Orange Book listing.
• Patent litigation, Paragraph IV challenges, licenses, and settlements cannot be determined from the claim language alone.

FAQs About US Patent 9,700,530

Does US 9,700,530 cover metoprolol succinate tablets?

No. The independent claims require an extended-release capsule dosage form containing coated discrete units. A conventional extended-release tablet would generally fall outside those limitations, although separate patents could apply.

Can a generic avoid the patent by using pellets larger than 1.5 mm?

Potentially, for claims requiring a d90 no higher than approximately 1.5 mm, but the result depends on the complete formulation and on how d90 is measured. Other patents or regulatory requirements may still apply.

Does a Paragraph IV filing automatically invalidate US 9,700,530?

No. A Paragraph IV certification is an applicant’s legal position that the patent is invalid, unenforceable, or not infringed. The patent owner may sue, and the court determines the outcome.

Are feeding-tube recovery claims product claims or method claims?

Claims 1 and 4 are drafted as dosage-form claims with functional performance limitations. The administration limitations in claims 8, 9, and 14 further narrow the claimed product configuration.

Is Kapspargo Sprinkle necessarily infringing if it has the same active ingredient?

No. Active-ingredient identity alone is insufficient. Infringement requires satisfaction of every limitation of an asserted claim, including dosage form, coating, particle size, stability, dissolution, or feeding-tube performance requirements.

References

1. U.S. Patent No. 9,700,530. (2017). Extended release capsule dosage form of metoprolol succinate. United States Patent and Trademark Office.

2. U.S. Food and Drug Administration. (n.d.-a). Kapspargo Sprinkle: Prescribing information. FDA.

3. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. FDA.

4. United States Code. (n.d.). 21 U.S.C. § 355(j), abbreviated applications and patent certifications.

5. United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information. USPTO.

Drugs Protected by US Patent 9,700,530

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Spil	KAPSPARGO SPRINKLE	metoprolol succinate	CAPSULE, EXTENDED RELEASE;ORAL	210428-001	Jan 26, 2018		RX	Yes	No			Y
Spil	KAPSPARGO SPRINKLE	metoprolol succinate	CAPSULE, EXTENDED RELEASE;ORAL	210428-002	Jan 26, 2018		RX	Yes	No			Y
Spil	KAPSPARGO SPRINKLE	metoprolol succinate	CAPSULE, EXTENDED RELEASE;ORAL	210428-003	Jan 26, 2018		RX	Yes	No			Y

International Family Members for US Patent 9,700,530

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015287299
Brazil	112017000468
Canada	2954474